You are here
Robert M. Califf, M.D., M.A.C.C.
Robert M. Califf was appointed to his position as Commissioner of Food and Drug for the U.S. Food and Drug Administration (FDA) in February 2016. As the top offiical of the FDA, Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health.
Previously he served as the FDA’s Deputy Commissioner for Medical Products and Tobacco. In that role he provided executive leadership to the Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Tobacco Products. He also oversaw the Office of Special Medical Programs and provided direction for cross-cutting clinical, scientific and regulatory initiatives, including personalized medicine, orphan drugs, pediatric science, and the advisory committee system.
He attended Duke University both as an undergraduate and for medical school, completing his residency at University of California, San Francisco, before returning to Duke for a cardiology fellowship. Dr. Califf served as the Donald F. Fortin, M.D., Professor of Cardiology at Duke and, most recently, Vice Chancellor for Clinical and Translational Research. An international leader in cardiovascular medicine, health outcomes, healthcare quality and medical economics, he is recognized by the Institute for Scientific Information as one of the top 10 most cited medical authors, with more than 1,200 peer-reviewed publications.
Dr. Califf co-chaired the Clinical Trials Transformation Initiative, a public-private partnership co-founded by Duke and the FDA to identify and promote practices that will increase the quality and efficiency of clinical trials. He also served as co-principal investigator of Duke’s Clinical and Translational Science Award, funded by the National Center for Advancing Translational Sciences; principal investigator for the coordinating center of the NIH Health Care Systems Research Collaboratory, a Common Fund program that develops, tests and disseminates innovative methodologies for pragmatic clinical research; and coprincipal investigator for the Baseline Study, a collaboration among Duke University, Stanford University, and Google that seeks new understandings of states of health and disease in humans.
This page last reviewed on June 14, 2016